US3924004A - Fatty alcohol-propylene carbonate-glycol solvent cream vehicle - Google Patents
Fatty alcohol-propylene carbonate-glycol solvent cream vehicle Download PDFInfo
- Publication number
- US3924004A US3924004A US201997A US20199771A US3924004A US 3924004 A US3924004 A US 3924004A US 201997 A US201997 A US 201997A US 20199771 A US20199771 A US 20199771A US 3924004 A US3924004 A US 3924004A
- Authority
- US
- United States
- Prior art keywords
- propylene carbonate
- weight percent
- glycol
- percent
- dione
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002904 solvent Substances 0.000 title claims description 12
- 239000006071 cream Substances 0.000 title description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 55
- 239000003814 drug Substances 0.000 claims abstract description 41
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 claims abstract description 30
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 150000002191 fatty alcohols Chemical class 0.000 claims abstract description 22
- 239000006184 cosolvent Substances 0.000 claims abstract description 21
- 239000004014 plasticizer Substances 0.000 claims abstract description 16
- 239000004094 surface-active agent Substances 0.000 claims abstract description 16
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 10
- 230000000087 stabilizing effect Effects 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 6
- 230000009286 beneficial effect Effects 0.000 claims description 4
- 239000003246 corticosteroid Substances 0.000 claims description 3
- 229960001334 corticosteroids Drugs 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 abstract description 13
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 8
- 229940124597 therapeutic agent Drugs 0.000 abstract description 6
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 3
- -1 glycerol fatty acid esters Chemical class 0.000 description 30
- 239000003981 vehicle Substances 0.000 description 30
- 239000002585 base Substances 0.000 description 21
- 235000014113 dietary fatty acids Nutrition 0.000 description 15
- 239000000194 fatty acid Substances 0.000 description 15
- 229930195729 fatty acid Natural products 0.000 description 15
- 239000004615 ingredient Substances 0.000 description 11
- 150000004665 fatty acids Chemical class 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 8
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 8
- 229920002125 Sokalan® Polymers 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 150000003431 steroids Chemical class 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 239000000344 soap Substances 0.000 description 5
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 235000011076 sorbitan monostearate Nutrition 0.000 description 4
- 239000001587 sorbitan monostearate Substances 0.000 description 4
- 229940035048 sorbitan monostearate Drugs 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 3
- 239000003945 anionic surfactant Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- ZZBWSNKBZKPGAK-UHFFFAOYSA-N chrysophanol-9-anthrone Chemical compound C1=CC=C2CC3=CC(C)=CC(O)=C3C(=O)C2=C1O ZZBWSNKBZKPGAK-UHFFFAOYSA-N 0.000 description 2
- 239000011280 coal tar Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 229960000735 docosanol Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- HSEMFIZWXHQJAE-UHFFFAOYSA-N hexadecanamide Chemical compound CCCCCCCCCCCCCCCC(N)=O HSEMFIZWXHQJAE-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- LYRFLYHAGKPMFH-UHFFFAOYSA-N octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(N)=O LYRFLYHAGKPMFH-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003883 ointment base Substances 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 229940093625 propylene glycol monostearate Drugs 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 229940012831 stearyl alcohol Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 210000002268 wool Anatomy 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- AIZJFEWNZRKHKA-UHFFFAOYSA-N (4-cyanophenyl)methyl phosphate;cyclohexylazanium Chemical compound [NH3+]C1CCCCC1.[NH3+]C1CCCCC1.[O-]P([O-])(=O)OCC1=CC=C(C#N)C=C1 AIZJFEWNZRKHKA-UHFFFAOYSA-N 0.000 description 1
- ISNWPDWXSHAYEL-KTORGGLSSA-N (6s,8s,9s,10r,13s,14s,17s)-17-acetyl-6,10,13-trimethyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](C(C)=O)CC[C@H]21 ISNWPDWXSHAYEL-KTORGGLSSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- KJDGFQJCHFJTRH-YONAWACDSA-N 16-Ketoestradiol Chemical class OC1=CC=C2[C@H]3CC[C@](C)([C@H](C(=O)C4)O)[C@@H]4[C@@H]3CCC2=C1 KJDGFQJCHFJTRH-YONAWACDSA-N 0.000 description 1
- PYHXGXCGESYPCW-UHFFFAOYSA-M 2,2-diphenylacetate Chemical compound C=1C=CC=CC=1C(C(=O)[O-])C1=CC=CC=C1 PYHXGXCGESYPCW-UHFFFAOYSA-M 0.000 description 1
- OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 1
- MLXDUYUQINCFFV-UHFFFAOYSA-N 2-acetyloxyacetic acid Chemical compound CC(=O)OCC(O)=O MLXDUYUQINCFFV-UHFFFAOYSA-N 0.000 description 1
- QAYNSPOKTRVZRC-UHFFFAOYSA-M 2-chloro-4-nitrobenzoate Chemical compound [O-]C(=O)C1=CC=C([N+]([O-])=O)C=C1Cl QAYNSPOKTRVZRC-UHFFFAOYSA-M 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- VRDBIJCCXDEZJN-UHFFFAOYSA-N 2-piperidin-1-ylacetic acid Chemical compound OC(=O)CN1CCCCC1 VRDBIJCCXDEZJN-UHFFFAOYSA-N 0.000 description 1
- UBLAMKHIFZBBSS-UHFFFAOYSA-N 3-Methylbutyl pentanoate Chemical compound CCCCC(=O)OCCC(C)C UBLAMKHIFZBBSS-UHFFFAOYSA-N 0.000 description 1
- NLJVXZFCYKWXLH-DXTIXLATSA-N 3-[(3r,6s,9s,12s,15s,17s,20s,22r,25s,28s)-20-(2-amino-2-oxoethyl)-9-(3-aminopropyl)-3,22,25-tribenzyl-15-[(4-hydroxyphenyl)methyl]-6-(2-methylpropyl)-2,5,8,11,14,18,21,24,27-nonaoxo-12-propan-2-yl-1,4,7,10,13,16,19,23,26-nonazabicyclo[26.3.0]hentriacontan Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(N[C@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)N1)=O)CC(C)C)C(C)C)C1=CC=C(O)C=C1 NLJVXZFCYKWXLH-DXTIXLATSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- DITDKJOHAAZUGD-UHFFFAOYSA-N 4-methyl-1,3-dioxolan-2-one;propane-1,2-diol Chemical compound CC(O)CO.CC1COC(=O)O1 DITDKJOHAAZUGD-UHFFFAOYSA-N 0.000 description 1
- AAOISIQFPPAFQO-UHFFFAOYSA-N 7:0(6Me,6Me) Chemical compound CC(C)(C)CCCCC(O)=O AAOISIQFPPAFQO-UHFFFAOYSA-N 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 239000004857 Balsam Substances 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- BUXDDNQBJRGXTB-DVFHKXEWSA-N CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)C=C(O)[C@]4(C)[C@H]3CC[C@]12C Chemical compound CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)C=C(O)[C@]4(C)[C@H]3CC[C@]12C BUXDDNQBJRGXTB-DVFHKXEWSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 241000581364 Clinitrachus argentatus Species 0.000 description 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
- YYLLIJHXUHJATK-UHFFFAOYSA-N Cyclohexyl acetate Chemical compound CC(=O)OC1CCCCC1 YYLLIJHXUHJATK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- ORAWFNKFUWGRJG-UHFFFAOYSA-N Docosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCC(N)=O ORAWFNKFUWGRJG-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241001517610 Funa Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- SSOXZAQUVINQSA-BTJKTKAUSA-N Pheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 SSOXZAQUVINQSA-BTJKTKAUSA-N 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108010021006 Tyrothricin Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- MKCUMRHZKMAABN-PUZWZNABSA-N [(8s,9s,10r,13s,14s,17s)-17-acetyl-10,13-dimethyl-3-oxo-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-1-yl] acetate Chemical compound C1C[C@@H]2[C@@]3(C)C(OC(=O)C)=CC(=O)C=C3CC[C@H]2[C@@H]2CC[C@H](C(C)=O)[C@]21C MKCUMRHZKMAABN-PUZWZNABSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005585 adamantoate group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- YTFJQDNGSQJFNA-UHFFFAOYSA-N benzyl dihydrogen phosphate Chemical compound OP(O)(=O)OCC1=CC=CC=C1 YTFJQDNGSQJFNA-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CSRVRWHGIOMHSO-UHFFFAOYSA-N benzyl phosphate;cyclohexylazanium Chemical compound [NH3+]C1CCCCC1.[NH3+]C1CCCCC1.[O-]P([O-])(=O)OCC1=CC=CC=C1 CSRVRWHGIOMHSO-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000008294 cold cream Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000004465 cycloalkenyloxy group Chemical group 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- MRKZAZMYXYSBDG-UHFFFAOYSA-N cyclopentyl propanoate Chemical compound CCC(=O)OC1CCCC1 MRKZAZMYXYSBDG-UHFFFAOYSA-N 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- HDFFVHSMHLDSLO-UHFFFAOYSA-M dibenzyl phosphate Chemical compound C=1C=CC=CC=1COP(=O)([O-])OCC1=CC=CC=C1 HDFFVHSMHLDSLO-UHFFFAOYSA-M 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- CRVGKGJPQYZRPT-UHFFFAOYSA-N diethylamino acetate Chemical compound CCN(CC)OC(C)=O CRVGKGJPQYZRPT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- BEZKAVDJYNAZJF-UHFFFAOYSA-L disodium;(2-methoxyphenyl) phosphate Chemical compound [Na+].[Na+].COC1=CC=CC=C1OP([O-])([O-])=O BEZKAVDJYNAZJF-UHFFFAOYSA-L 0.000 description 1
- YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
- AKMLXRWHUXQISP-UHFFFAOYSA-L disodium;benzyl phosphate Chemical compound [Na+].[Na+].[O-]P([O-])(=O)OCC1=CC=CC=C1 AKMLXRWHUXQISP-UHFFFAOYSA-L 0.000 description 1
- ANLFRXGAWNYDEJ-UHFFFAOYSA-L disodium;ethyl phosphate Chemical compound [Na+].[Na+].CCOP([O-])([O-])=O ANLFRXGAWNYDEJ-UHFFFAOYSA-L 0.000 description 1
- FVSQINWXQVPJDN-UHFFFAOYSA-L disodium;phenacyl phosphate Chemical compound [Na+].[Na+].[O-]P([O-])(=O)OCC(=O)C1=CC=CC=C1 FVSQINWXQVPJDN-UHFFFAOYSA-L 0.000 description 1
- TYJOJLOWRIQYQM-UHFFFAOYSA-L disodium;phenyl phosphate Chemical compound [Na+].[Na+].[O-]P([O-])(=O)OC1=CC=CC=C1 TYJOJLOWRIQYQM-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- RNYJXPUAFDFIQJ-UHFFFAOYSA-N hydron;octadecan-1-amine;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[NH3+] RNYJXPUAFDFIQJ-UHFFFAOYSA-N 0.000 description 1
- 229940027897 ichthammol Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- WRWRKDRWMURIBI-UHFFFAOYSA-M mercuric amidochloride Chemical compound N[Hg]Cl WRWRKDRWMURIBI-UHFFFAOYSA-M 0.000 description 1
- 229960000432 mercuric amidochloride Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- RMIODHQZRUFFFF-UHFFFAOYSA-M methoxyacetate Chemical compound COCC([O-])=O RMIODHQZRUFFFF-UHFFFAOYSA-M 0.000 description 1
- GTDAIQOQQBNVOH-UHFFFAOYSA-N methyl 2-[hydroxy(phenylmethoxy)phosphoryl]oxybenzoate Chemical compound COC(=O)C1=CC=CC=C1OP(O)(=O)OCC1=CC=CC=C1 GTDAIQOQQBNVOH-UHFFFAOYSA-N 0.000 description 1
- YSEQYIDUBUJABL-UHFFFAOYSA-N methyl 4,4-dimethylpentanoate Chemical compound COC(=O)CCC(C)(C)C YSEQYIDUBUJABL-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
- 229960001907 nitrofurazone Drugs 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-M nonanoate Chemical compound CCCCCCCCC([O-])=O FBUKVWPVBMHYJY-UHFFFAOYSA-M 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- ZHALDANPYXAMJF-UHFFFAOYSA-N octadecanoate;tris(2-hydroxyethyl)azanium Chemical compound OCC[NH+](CCO)CCO.CCCCCCCCCCCCCCCCCC([O-])=O ZHALDANPYXAMJF-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- FATBGEAMYMYZAF-UHFFFAOYSA-N oleicacidamide-heptaglycolether Natural products CCCCCCCCC=CCCCCCCCC(N)=O FATBGEAMYMYZAF-UHFFFAOYSA-N 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008040 pharmaceutical emulsifying agent Substances 0.000 description 1
- 239000008251 pharmaceutical emulsion Substances 0.000 description 1
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 235000011185 polyoxyethylene (40) stearate Nutrition 0.000 description 1
- 239000001194 polyoxyethylene (40) stearate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
- 229960003656 ricinoleic acid Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- AUPJTDWZPFFCCP-GMFCBQQYSA-M sodium;2-[methyl-[(z)-octadec-9-enyl]amino]ethanesulfonate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCCN(C)CCS([O-])(=O)=O AUPJTDWZPFFCCP-GMFCBQQYSA-M 0.000 description 1
- FGDMJJQHQDFUCP-UHFFFAOYSA-M sodium;2-propan-2-ylnaphthalene-1-sulfonate Chemical compound [Na+].C1=CC=CC2=C(S([O-])(=O)=O)C(C(C)C)=CC=C21 FGDMJJQHQDFUCP-UHFFFAOYSA-M 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940037312 stearamide Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229940066528 trichloroacetate Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229940029614 triethanolamine stearate Drugs 0.000 description 1
- 229960003281 tyrothricin Drugs 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Definitions
- ointment a preparation containing active medications that can be readily applied and rubbed into the skin. It serves as a means for distributing the medication uniformly over the skin surface and maintaining it there until beneficial action can occur.
- the earliest ointment preparations were based on fats, waxes, greases and petrolatum. These are, by nature, greasy, or not waterwashable and having a limited ability to release medication to the skin.
- a non-aqueous ointment of more recent origin is a mixture of polyethylene glycols having molecular weights of 1,000 to 20,000. This vehicle, although water-washable, has a greasy texture and does not provide an occlusive dressing on a treated surface.
- these anhydrous ointment bases were the only vehicles available for medicaments which deteriorated in the presence of moisture.
- Emulsified creams such as cold creams, were developed to reduce greasiness, while still maintaining the unctuousness and spreadability of the older greasy-type ointments.
- the emulsified creams have an aqueous base, however, and are not suitable for many drugs be cause their water content destroy the medicament.
- the medicament in turn may destroy the emulsions, that is,
- composition of this invention is a substantially anhydrous vehicle composition consisting essentially of a. from 5 to 40 weight percent of saturated fatty alcohol having from 16 to 24 carbons;
- glycol cosolvent from 25 to 85 weight percent of glycol cosolvent, the weight ratio of the glycol solvent to propylene carbonate being at least 1:2;
- the base is an improved vehicle for all types of therapeutic agents for topical application and offers particular advantages with anti-inflammatory topical steroids.
- the composition of this invention contains from 5 to 40 and preferably from 10 to 30 percent fatty alcohol.
- the fatty alcohol can be any fatty alcohol having from 16 to 24 carbons or mixtures thereof, and is preferably a saturated monohydric primary alcohol. Suitable fatty alcohols include cetyl alcohol, stearyl alcohol, behenyl alcohol, and the like.
- the fatty alcohol component should be substantially free from any significant amount of unsaturated alcohols or fatty alcohols having fewer than 16 carbons, the term substantially free from as used herein, is defined as indicating the compositions of this invention containing less than irritating or otherwise medically undesirable amounts of the indicated substances. Since the commercially available fatty alcohols having from 16 to 24 carbons contain impurities including some proportion of fatty alcohols having fewer than 16 carbons, total avoidance of alcohols having fewer than 16 carbons from the mixture is not practicable. Careful selection of raw materials is preferable, however, to maintain the percentage of irritating alcohols to less than l0 percent of the total fatty alcohol concentration.
- composition of this invention also contains from 1 to 40 and preferably from 5 to 30 percent propylene carbonate.
- the composition of this invention also contains a stabilizing amount of a surfactant, that is, an amount sufficient to maintain homogeneity of the other ingredients.
- a stabilizing amount of a surfactant that is, an amount sufficient to maintain homogeneity of the other ingredients.
- concentration will vary depending upon the choice of surfactant and the selection of the other ingredients. in general, stabilizing amounts can be as low as 0.1 percent or lower. In some instances as high as percent or higher of surfactant may be desired. Generally from 2 to 5 percent is suitable.
- the amount of surfactant should be the minimum required for stability.
- the surfactant functions as a coupling agent, linking diverse phases and maintaining a dispersion of irnmisicible components. Suitable surfactants include pharmaceutically acceptable, non-toxic non-ionic, anionic and cationic surfactants.
- non-ionic surfactants include glycerol fatty acid esters such as glycerol monostearate, glycol fatty acid esters such as propylene glycol monostearate, polyhydric alcohol fatty acid esters such as sorbitan monostearate, polyethylene glycol fatty acid esters such as polyethylene glycol (400) monooleate, polyoxyethylene fatty acid esters such as polyoxyethylene (40) stearate, polyoxyethylene fatty alcohol ethers such as polyoxyethylene (20) stearyl ether, polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene sorbitan monostearate, fatty acid ethanolamides and their derivatives such as the diethanolamide of stearic acid, and the like.
- glycerol fatty acid esters such as glycerol monostearate
- glycol fatty acid esters such as propylene glycol monostearate
- polyhydric alcohol fatty acid esters such as sorbitan monostearate
- Suitable anionic surfactants are soaps including alkali soaps, such as sodium, potassium and ammonium salts of aliphatic carboxylic acids, usually fatty acids, such as sodium stearate.
- alkali soaps such as sodium, potassium and ammonium salts of aliphatic carboxylic acids, usually fatty acids, such as sodium stearate.
- Organic amine soaps also included, include organic amine salts of aliphatic carboxylic acids, usually fatty acids, such as triethanolamine stearate.
- Another class of suitable soaps is the metallic soaps, salts ofspolyvalent metals and aliphatic carboxylic acids, usually fatty acids, such as aluminum stearate.
- Suitable anionic surfactants include sulfated fatty alcohols such as sodium lauryl sulfate, sulfated oils such as the sulfuric ester of ricinoleic acid disodium salt, and sulfonated compounds such as alkyl sulfonates including sodium cetane sulfonate, amide sulfonates such as sodium N- methyl-N-oleyl taurate, sulfonated dibasic acid esters such as sodium dioctyl sulfosuccinate, alkyl aryl sulfonates such as sodium dodecylbenzene sulfonate, alkyl naphthalene sulfonates such as sodium isopropyl naphthalene sulfonate, petroleum sulfonates such as arylnaphthene with alkyl substituents.
- sulfated fatty alcohols such as sodium lauryl sulf
- Suitable cationic surfactants include amine salts such as octadecyl ammonium chloride, quaternary ammonium compounds such as benzalkonium chloride.
- amine salts such as octadecyl ammonium chloride, quaternary ammonium compounds such as benzalkonium chloride.
- Other examples of these and other suitable surfactants can be found in Pharmaceutical Emulsions and Emulsifying Agents by Lawrence M. Spatton, second edition, The Chemist and Druggist, London; Emulsions; Theory and Practice by Paul Becher, Reinhold Publishing Corporation, New York; and Detergents and Emulsificers, 1969 Annual by John M. McCutcheon, Morriston, N.J., the disclosures thereof being incorporated herein by reference.
- the composition of this invention can also contain from 0 to and preferably from 0.1 to 5 percent of a compatible plasticizer.
- suitable compatible plasticizers include carboxylic vinyl polymers (Carbopols), polyethylene glycol having a molecular weight of from above 800 to 20,000; natural gums including acacia gum, guar gum, karaya, tragacanth, and the like; seaweed products such as agar, irish moss and alginates; cellulose derivatives including cellulose ethers such as methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose and the like; starch, starch derivatives and dextrins; pectin and pectates; saponins; and water soluble or water dispersible vinyl polymers such as polyvinylpyrrolidone, polyvinyl alcohol, vinyl pyrrolidonevinyl alcohol copolymers, and the like.
- the plasticizer maintains homogeneity in the mixture at ambient temperatures, that is, temperatures at which the fatty alcohol is a solid. This component also improves the plasticity, and uniformity of the medicament mixtures with the vehicle and provides to the vehicle smoothness and a more pleasing feel; hence the vehicle containing the plasticizer is more cosmetically acceptable.
- the particular plasticizer concentration necessary to provide a desired consistency, degree of smoothness and plasticity will vary with the choice of the fatty alcohol component and cosolvent, and the ratio of these components in the vehicle.
- the plasticizer concentration should be balanced so the vehicle has freeze-thaw stability, i.e., does not separate after repeated cycles of solidification (by cooling) and liquefaction (by heating).
- the term compatible is defined herein to indicate a component which will not cause separation (loss of homogeneity) of the other components at temperatures up to 45C.
- the medicament vehicles of this invention can also contain other non-essential ingredients.
- the vehicle can contain up to l0 weight percent of conventional pharmaceutical adjuvants. These adjuvants or additives are used to improve consistency, emolliency, homogeneity, spreadability, texture and appearance of the vehicle or its residual film or the stability of the medicament. They can be used to give a residual film, varying degrees of continuity, flexibility, adhesion, occlusion, water repellancy, washability, and the like.
- Suitable auxiliary adjuvants include hydrocarbons ranging from liquid petrolatum to solid paraffins and waxes, beeswax, saturated fatty acids having from 16 to 24 carbons such as stearic acid, palmitic acid, behenic acid; fatty acid amides such as oleamide, palmitamide, stearamide, behenamide; and esters of fatty acids having'from 14 to 24 carbons such as isopropyl myristate sorbitan monostearate, polyethylene glycol monostearate, propylene glycol monostearate and the corresponding monoand diesters of other fatty acids such as oleic and acid and palmitic acid.
- hydrocarbons ranging from liquid petrolatum to solid paraffins and waxes, beeswax, saturated fatty acids having from 16 to 24 carbons such as stearic acid, palmitic acid, behenic acid; fatty acid amides such as oleamide, palmitamide, stearamide, behen
- the fatty acids be saturated and the fatty acids and amides be substantially free from irritating amounts of acids or amides having fewer than l4 carbons.
- Other optional adjuvants include miscellaneous natural products such as wool fat, wool alcohol, cholesterol and its derivatives, lecithin and proteins such as gelatin, casein, soyabean protein, egg albumen.
- Finely dispersed mineral solids useful as thickeners include colloidal clays such as bentonite and polyvalent metal hydroxides such as magnesium hydroxide.
- Suitable chemical stabilizers include citric acid and other agents to adjust pH, ethylenediamine tetraacetic acid and its salts and other chelating or sequestering agents, propyl gallate, butylated hydroxy anisole or toluene, and other 1 6 antioxidants.
- I by conventional techniques.
- the medicament vehicle of this invention is essenshould be mixed beforehand with a small proportion of tially a non-aqueous base, that is, it is not an aqueous the base mixture, propylene carbonate, or propylene emulsion and consequently is not a cream in the glycol, and then blended with the remainder of the usual sense. It is preferably totally anhydrous, but can base.
- the products are usually improved by passing contain minor amounts of water such as up to 3 percent them through an ointment or roller mill.
- the water concentration should not be sufficient th m l, b l m P ru and other that require special to cause separation of the other vehicle components or processing in greasy bases can be readily incorporated precipita e medicam nts dis l ed in h hi l 10 in the base of this invention.
- the medicaments can be The ehicle Of this n ent can b made thoroughly incorporated into the final base or introduced into the mixing the components at ambient or elevated p base mixture with one of its components.
- Heat sensitive fltllfes Preferably the components are thoroughly medicaments (in particular some antibiotics) can be mixed while each is in a liquid state, and the mixture is di l d suspended i a small amount of propylene Cooled with good agitation to room temperature Pfefcarbonate, glycol cosolvent or other liquid, and then erably, additional mechanical agitation and/0r Shock mixed with the vehicle during or after its preparation.
- Th amount f dica nt to be incorporated into the manufacturing process 110 impart more homogenethe base of course depend upon the type of mediity of improved teXture' Process equipment for these cament and its intended use; the determination of suittechniques includes heat exchangers, Propeller mixers, 2O able medicament concentrations is a routine matter Colloid mills, hom g iz r roller mills and the likefully within the conventional skill of the art.
- the base Of this invention can be used as a Vehicle for therapeutically effective amounts of the medicament all types of medicaments or therapeutic agents for topiare incorporated i h hi l Cal application including antibiotics such as y y
- the vehicle of this invention is particularly suitable Cline, chloftetl'acyclinei streptomycin, bacitracin, 01110- 5 for use with anti-inflammatory topical steroids repreramphenicol, tyrothricin and the like; steroids having ented b F l I, II and III.
- tamines such as prophenpyridamine maleate and di- R1 is hy r gen, methyl, flu0r0,or chloro and when Z phenhydramine hydrochloride; anesthetics such as is a single bond, R, can be either a or B oriented; benzocaine and lidocaine; antibacterials including io- 2 is hy g n, chloro, dine; iodochlorohydroxyquin, nitrofurazone, sulfanila- 3 is ketO mide and derivatives, and behzalkonium chloride; funa glcldes such as undecylentc acid vitamins such as Vitamin A derivatives; and other therapeutic agents including coal tar, balsam Peru, ammoniated mercury, anwherein R is hydrogen, hydroxy, chloro, or fluoro; thralin, chrysarobin,
- R is hydrogen, hydroxy, a conventional hydrolyzable ester thereof, or when taken together with R,,',
- R is hydrogen or alkyl of up to eight carbons
- R is hydrogen, or alkyl or an aryl group of up to eight carbons
- R is hydroxy, conventional hydrolyzable esters thereof, tetrahydropyranyloxy, tetrahydrofuranyloxy, 4-(lower)alkoxytetrahydropyran-4-yloxy, lower alkoxy, lower cycloalkoxy, lower cycloalkenyloxy, chloro, or fluoro;
- R and R are hydrogen, methyl, phenyl, chlorophenyl, fluorophenyl, methylphenyl, or methoxyphenyl (the substituted phenyls preferably being substituted in the para position);
- R and R each is hydrogen, chloro or fluoro
- Z, and Z each is a single bond, double bond, or
- alkyl groups having from one to six carbon atoms, inclusive, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, amyl, hexyl, and the like.
- hydrolyzable ester denotes those hydrolyzable ester groups conventional employed in the steriod art, preferably those derived from hydrocarbon carboxylic acids or phosphoric acids and their salts.
- hydrocarbon carboxylic acid defines both substituted and unsubstituted hydrocarbon carboxylic acids. These acids can be completely saturated or possess varying degrees of unsaturation (including aromatic), can be of straight chain, branched chain, or cyclic structure, and preferably contain from one to 12 carbon atoms.
- Typical conventional hydrolyzable esters thus included within the scope of the term and the instant invention are acetate, propionate, butyrate, valerate, caproate, enanthate, caprylate, pelargonate, acrylate, undecenoate, phenoxyacetate, benzoate, phenylacetate, diphenylacetate, diethylacetate, trimethylacetate, t-butylacetate, trimethylhexanoate, methylneopentylacetate, cyclohexylacetate, cyclopentylpropionate, adamantoate, glycolate, methoxyacetate, hemisuccinate, hemiadipate, hemi-B,B-dimethylglutarate, acetoxyacetate, 2-chloro-4-nitrobenzoate, aminoacetate, diethylaminoacetate, piperidinoacetate, B-chloropropionate, trichloroacetate, B-chlorobutyrate, di
- aryl are included aryl, aralkyl, and alkaryl groups, such as phenyl, p-chlorophenyl, pmethoxyphenyl, benzyl, phen'ethyl, tolyl, ethylphenyl, and the like.
- the wavy line I designates and includes both the alpha and beta configurations.
- the above anti-inflammatory topical medicaments are thoroughly mixed with the base in therapeutically effective amounts.
- concentration of the medicament in the base will vary depending upon the particular activity of the steroid used considered in conjunction with the condition and subject to be treated.
- therapeutically effective amounts of these compounds can be as low as 0.00001 weight percent or lower, for example.
- as high as 5 weight percent steroid or higher may be desired.
- the medicament base of this invention has been found to be particularly suitable for use with topical corticoids, for example, 6a-fluoro-11 B-hydroxy- 16a,17a-isopropylidenedioxy-2lacetoxypregna-l ,4-diene-3 ,20-dione, fluocinolone acetonide (6a,9a-
- EXAMPLE 1 The following ingredients are mixed at 80C and cooled to room temperature with good agitation.
- EXAMPLE 4 Each of 0.25, 0.5 and 1.0 gm. quantities of the following anti-inflammatory steroids, when incorporated into 1,000 gm. the mixtures described in Example 1, are effective for topical treatment of inflammation:
- EXAMPLE 5 Repeating the procedure of Example 1 with a. from 5 to 40 percent of a fatty alcohol having from 16 to 24 carbons, e.g. cetyl alcohol, stearyl alcohol, behenyl alcohol, etc.;
- glycol cosolvent such as 1,2-
- a stabilizing quantity of a surfactant such as sorbitan monooleate d. a stabilizing quantity of a surfactant such as sorbitan monooleate
- Carbopol carboxy vinyl polymer
- a substantially anhydrous vehicle composition consisting essentially of a. from 5 to 40 weight percent of saturated fatty alcohol having from 16 to 24 carbons;
- weight ratio of the glycol solvent to propylene carbonate being at least 1:2;
- vehicle composition being particularly suitable for providing an occlusive film, for releasing topically active cortico-steroids which are soluble in propylene carbonate, and for distributing medication over the skin surface and maintaining it there until beneficial action occurs.
- composition of claim 1 comprising a. from to 30 weight percent of saturated fatty alcohol having from 16 to 24 carbons;
- the weight ratio of glycol solvent to propylene carbonate being at least 1:1;
- composition of claim 2 wherein the compatible plasticizer concentration is from 0.1 to 5 weight percent.
- composition of claim 1 wherein the weight ratio of the glycol cosolvent to propylene carbonate is at least 1:1.
- composition of claim 1 wherein the weight ratio of the glycol cosolvent to propylene carbonate is
Landscapes
- Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
A medicament base containing from 5 to 40 percent saturated fatty alcohol having from 16 to 24 carbons, from 1 to 40 percent propylene carbonate, from 25 to 85 percent of glycol cosolvent, a stabilizing amount of a surfactant and optional amounts of compatible plasticizer, and/or other pharmaceutical adjuvants. The base is a suitable vehicle for all types of therapeutic agents for topical application and has shown particular advantages with anti-inflammatory topical corticoids.
Description
United States Patent [191 Chang et al.
[ Dec. 2, 1975 1 FATTY ALCOHOL-PROPYLENE CARBONATE-GLYCOL SOLVENT CREAM VEHICLE [75] Inventors: Kuang Y. Chang, Palo Alto, Calif.;
Bonnie Ferrell, Clinton, NY,
[73] Assignee: Syntex Corporation, Palo Alto,
Calif.
[22] Filed: Nov. 24, 1971 21 Appl. No.: 201,997
Lerner 424/241 X 3,472,931 10/1969 Stoughton.. 424/240 X 3,574,118 4/1971 Baker 1 424/73 3,592,930 7/1971 Katz et al 424/243 FOREIGN PATENTS OR APPLICATIONS 1,096,753 12/1967 United Kingdom 1,448,042 6/1966 France Primary ExaminerShep K. Rose Attorney, Agent, or Firm-Joesph I. Hirsch; Thomas M. Moran; William E. Walker [57] ABSTRACT A medicament base containing from 5 to 40 percent saturated fatty alcohol having from 16 to 24 carbons, from 1 to 40 percent propylene carbonate, from 25 to 85 percent of glycol cosolvent, a stabilizing amount of a surfactant and optional amounts of compatible plasticizer, and/or other pharmaceutical adjuvants. The base is a suitable vehicle for all types of therapeutic agents for topical application and has shown particular advantages with anti-inflammatory topical corticoids.
5 Claims, No Drawings FATTY ALCOHOL-PROPYLENE CARBONATE-GLYCOL SOLVENT CREAM VEHICLE BACKGROUND OF THE INVENTION This invention relates to vehicles for topical application of medicaments and to mixtures of the vehicle and medicaments. In particular, this invention relates to new, improved medicament vehicles having advantages over previously known vehicles.
One of the oldest types of medicament vehicles is the ointment, a preparation containing active medications that can be readily applied and rubbed into the skin. It serves as a means for distributing the medication uniformly over the skin surface and maintaining it there until beneficial action can occur. The earliest ointment preparations were based on fats, waxes, greases and petrolatum. These are, by nature, greasy, or not waterwashable and having a limited ability to release medication to the skin. A non-aqueous ointment of more recent origin is a mixture of polyethylene glycols having molecular weights of 1,000 to 20,000. This vehicle, although water-washable, has a greasy texture and does not provide an occlusive dressing on a treated surface. Prior to this invention, these anhydrous ointment bases were the only vehicles available for medicaments which deteriorated in the presence of moisture.
Emulsified creams, such as cold creams, were developed to reduce greasiness, while still maintaining the unctuousness and spreadability of the older greasy-type ointments. The emulsified creams have an aqueous base, however, and are not suitable for many drugs be cause their water content destroy the medicament. The medicament, in turn may destroy the emulsions, that is,
break the emulsions and permit separation of the vehicle components. Furthermore, water is frequently not desirable in a medicament formulation because of its adverse effects on a condition being treated.
One system which is not subject to the above disadvantages is the non-aqueousfatty alcohol propylene glycol vehicles described in US. Pat. No. 3,592,930 granted to Katz et al. The subject of this invention is an improved non-aqueous vehicle with a propylene carbonate solvent system.
It is accordingly the purpose of this invention to provide an essentially anhydrous, water-washable base which is more effective than standard anhydrous ointment bases of the grease type because it can preserve the activity of medicaments which deteriorate in the presence of moisture; provide an occlusive film for longer and better therapeutic activity; release the medicaments more quickly and effectively; bring dissolved therapeutic agents in known dilution in contact with the skin; spread evenly and adhere well even if the skin is moist; be readily removed from the skin or fabrics with water; provide media to readily absorb discharges from wounds; serve as an excellent levigating material for many prescribed ingredients that usually require separate treatment before being incorporated into one of the bases; provide a base for medicament formulations in which water is not desired; and because it does not hydrolyze, deteriorate, become rancid, support mold growth or require preservatives.
It is a further object of this invention to provide a vehicle using a unique solvent, new for topical preparations. Propylene carbonate has exceptional solubilizing properties, particularly for corticosteroids. By combining a glycol cosolvent and surfactant with the fatty alcohol and propylene carbonate, a stable cream can be prepared. Further, by varying the ratio of propylene carbonate and glycol cosolvent one can obtain a wide range of saturation concentrations for a medicament. Thus the ratio can be chosen to optimize drug delivery for any particular medicament.
SUMMARY The composition of this invention is a substantially anhydrous vehicle composition consisting essentially of a. from 5 to 40 weight percent of saturated fatty alcohol having from 16 to 24 carbons;
b. from I to 40 weight percent of propylene carbonate;
c. from 25 to 85 weight percent of glycol cosolvent, the weight ratio of the glycol solvent to propylene carbonate being at least 1:2;
d. a stabilizing amount of surfactant; and
e. from 0 to 15 weight percent of compatible plasticizer. The base is an improved vehicle for all types of therapeutic agents for topical application and offers particular advantages with anti-inflammatory topical steroids.
DESCRIPTION OF THE PREFERRED EMBODIMENTS All concentrations are herein given as weight percents unless otherwise specified. It is also intended that the chemical compounds in each class of ingredients discussed hereinafter be limited to pharmaceutically acceptable, non-toxic compounds in the concentrations indicated.
The composition of this invention contains from 5 to 40 and preferably from 10 to 30 percent fatty alcohol. The fatty alcohol can be any fatty alcohol having from 16 to 24 carbons or mixtures thereof, and is preferably a saturated monohydric primary alcohol. Suitable fatty alcohols include cetyl alcohol, stearyl alcohol, behenyl alcohol, and the like.
The fatty alcohol component should be substantially free from any significant amount of unsaturated alcohols or fatty alcohols having fewer than 16 carbons, the term substantially free from as used herein, is defined as indicating the compositions of this invention containing less than irritating or otherwise medically undesirable amounts of the indicated substances. Since the commercially available fatty alcohols having from 16 to 24 carbons contain impurities including some proportion of fatty alcohols having fewer than 16 carbons, total avoidance of alcohols having fewer than 16 carbons from the mixture is not practicable. Careful selection of raw materials is preferable, however, to maintain the percentage of irritating alcohols to less than l0 percent of the total fatty alcohol concentration.
The composition of this invention also contains from 1 to 40 and preferably from 5 to 30 percent propylene carbonate.
The composition of this invention also contains from 25 to preferably from 30 to 80 percent of glycol cosolvent. Suitable glycol cosolvents include l,2- propanediol, l,3-propanediol, polyethylene glycol having a molecular weight of from to 800, dipropylene glycol, and the like or mixtures thereof. The weight ratio of glycol cosolvent to propylene carbonate must be at least 1:2 to provide a stable composition. It is preferably at least lzl, and the optimum ratio is at least 3:l. In the absence of the glycol cosolvent, the propylene carbonate and fatty alcohol do not form a physically stable mixture. Thus, the glycol cosolvent functions primarily as a coupling ingredient for the fatty alcohol and propylene carbonate. it also functions as an auxiliary solvent in the system.
The composition of this invention also contains a stabilizing amount of a surfactant, that is, an amount sufficient to maintain homogeneity of the other ingredients. The particular concentration will vary depending upon the choice of surfactant and the selection of the other ingredients. in general, stabilizing amounts can be as low as 0.1 percent or lower. In some instances as high as percent or higher of surfactant may be desired. Generally from 2 to 5 percent is suitable. The amount of surfactant should be the minimum required for stability. The surfactant functions as a coupling agent, linking diverse phases and maintaining a dispersion of irnmisicible components. Suitable surfactants include pharmaceutically acceptable, non-toxic non-ionic, anionic and cationic surfactants. Examples of suitable non-ionic surfactants include glycerol fatty acid esters such as glycerol monostearate, glycol fatty acid esters such as propylene glycol monostearate, polyhydric alcohol fatty acid esters such as sorbitan monostearate, polyethylene glycol fatty acid esters such as polyethylene glycol (400) monooleate, polyoxyethylene fatty acid esters such as polyoxyethylene (40) stearate, polyoxyethylene fatty alcohol ethers such as polyoxyethylene (20) stearyl ether, polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene sorbitan monostearate, fatty acid ethanolamides and their derivatives such as the diethanolamide of stearic acid, and the like. Examples of suitable anionic surfactants are soaps including alkali soaps, such as sodium, potassium and ammonium salts of aliphatic carboxylic acids, usually fatty acids, such as sodium stearate. Organic amine soaps, also included, include organic amine salts of aliphatic carboxylic acids, usually fatty acids, such as triethanolamine stearate. Another class of suitable soaps is the metallic soaps, salts ofspolyvalent metals and aliphatic carboxylic acids, usually fatty acids, such as aluminum stearate. Other classes of suitable anionic surfactants include sulfated fatty alcohols such as sodium lauryl sulfate, sulfated oils such as the sulfuric ester of ricinoleic acid disodium salt, and sulfonated compounds such as alkyl sulfonates including sodium cetane sulfonate, amide sulfonates such as sodium N- methyl-N-oleyl taurate, sulfonated dibasic acid esters such as sodium dioctyl sulfosuccinate, alkyl aryl sulfonates such as sodium dodecylbenzene sulfonate, alkyl naphthalene sulfonates such as sodium isopropyl naphthalene sulfonate, petroleum sulfonates such as arylnaphthene with alkyl substituents. Examples of suitable cationic surfactants include amine salts such as octadecyl ammonium chloride, quaternary ammonium compounds such as benzalkonium chloride. Other examples of these and other suitable surfactants can be found in Pharmaceutical Emulsions and Emulsifying Agents by Lawrence M. Spatton, second edition, The Chemist and Druggist, London; Emulsions; Theory and Practice by Paul Becher, Reinhold Publishing Corporation, New York; and Detergents and Emulsificers, 1969 Annual by John M. McCutcheon, Morriston, N.J., the disclosures thereof being incorporated herein by reference.
The composition of this invention can also contain from 0 to and preferably from 0.1 to 5 percent ofa compatible plasticizer. Suitable compatible plasticizers include carboxylic vinyl polymers (Carbopols), polyethylene glycol having a molecular weight of from above 800 to 20,000; natural gums including acacia gum, guar gum, karaya, tragacanth, and the like; seaweed products such as agar, irish moss and alginates; cellulose derivatives including cellulose ethers such as methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose and the like; starch, starch derivatives and dextrins; pectin and pectates; saponins; and water soluble or water dispersible vinyl polymers such as polyvinylpyrrolidone, polyvinyl alcohol, vinyl pyrrolidonevinyl alcohol copolymers, and the like. The plasticizer maintains homogeneity in the mixture at ambient temperatures, that is, temperatures at which the fatty alcohol is a solid. This component also improves the plasticity, and uniformity of the medicament mixtures with the vehicle and provides to the vehicle smoothness and a more pleasing feel; hence the vehicle containing the plasticizer is more cosmetically acceptable. In general, the particular plasticizer concentration necessary to provide a desired consistency, degree of smoothness and plasticity will vary with the choice of the fatty alcohol component and cosolvent, and the ratio of these components in the vehicle. Preferably, the plasticizer concentration should be balanced so the vehicle has freeze-thaw stability, i.e., does not separate after repeated cycles of solidification (by cooling) and liquefaction (by heating). The term compatible is defined herein to indicate a component which will not cause separation (loss of homogeneity) of the other components at temperatures up to 45C.
It should be understood that the medicament vehicles of this invention can also contain other non-essential ingredients. The vehicle can contain up to l0 weight percent of conventional pharmaceutical adjuvants. These adjuvants or additives are used to improve consistency, emolliency, homogeneity, spreadability, texture and appearance of the vehicle or its residual film or the stability of the medicament. They can be used to give a residual film, varying degrees of continuity, flexibility, adhesion, occlusion, water repellancy, washability, and the like. Suitable auxiliary adjuvants include hydrocarbons ranging from liquid petrolatum to solid paraffins and waxes, beeswax, saturated fatty acids having from 16 to 24 carbons such as stearic acid, palmitic acid, behenic acid; fatty acid amides such as oleamide, palmitamide, stearamide, behenamide; and esters of fatty acids having'from 14 to 24 carbons such as isopropyl myristate sorbitan monostearate, polyethylene glycol monostearate, propylene glycol monostearate and the corresponding monoand diesters of other fatty acids such as oleic and acid and palmitic acid. It is preferable that the fatty acids be saturated and the fatty acids and amides be substantially free from irritating amounts of acids or amides having fewer than l4 carbons. Other optional adjuvants include miscellaneous natural products such as wool fat, wool alcohol, cholesterol and its derivatives, lecithin and proteins such as gelatin, casein, soyabean protein, egg albumen. Finely dispersed mineral solids useful as thickeners include colloidal clays such as bentonite and polyvalent metal hydroxides such as magnesium hydroxide. Suitable chemical stabilizers include citric acid and other agents to adjust pH, ethylenediamine tetraacetic acid and its salts and other chelating or sequestering agents, propyl gallate, butylated hydroxy anisole or toluene, and other 1 6 antioxidants. I i by conventional techniques. A bulky, insoluble powder The medicament vehicle of this invention is essenshould be mixed beforehand with a small proportion of tially a non-aqueous base, that is, it is not an aqueous the base mixture, propylene carbonate, or propylene emulsion and consequently is not a cream in the glycol, and then blended with the remainder of the usual sense. It is preferably totally anhydrous, but can base. The products are usually improved by passing contain minor amounts of water such as up to 3 percent them through an ointment or roller mill. Coal tar, ichwater. The water concentration should not be sufficient th m l, b l m P ru and other that require special to cause separation of the other vehicle components or processing in greasy bases can be readily incorporated precipita e medicam nts dis l ed in h hi l 10 in the base of this invention. The medicaments can be The ehicle Of this n ent can b made thoroughly incorporated into the final base or introduced into the mixing the components at ambient or elevated p base mixture with one of its components. Heat sensitive fltllfes- Preferably the components are thoroughly medicaments (in particular some antibiotics) can be mixed while each is in a liquid state, and the mixture is di l d suspended i a small amount of propylene Cooled with good agitation to room temperature Pfefcarbonate, glycol cosolvent or other liquid, and then erably, additional mechanical agitation and/0r Shock mixed with the vehicle during or after its preparation. cooling steps are used as intermediate or final steps in Th amount f dica nt to be incorporated into the manufacturing process 110 impart more homogenethe base of course depend upon the type of mediity of improved teXture' Process equipment for these cament and its intended use; the determination of suittechniques includes heat exchangers, Propeller mixers, 2O able medicament concentrations is a routine matter Colloid mills, hom g iz r roller mills and the likefully within the conventional skill of the art. In general, The base Of this invention can be used as a Vehicle for therapeutically effective amounts of the medicament all types of medicaments or therapeutic agents for topiare incorporated i h hi l Cal application including antibiotics such as y y The vehicle of this invention is particularly suitable Cline, chloftetl'acyclinei streptomycin, bacitracin, 01110- 5 for use with anti-inflammatory topical steroids repreramphenicol, tyrothricin and the like; steroids having ented b F l I, II and III.
(I) (II) (III) anti-inflammatory or other beneficial activity; antihis- In the above formulas tamines such as prophenpyridamine maleate and di- R1 is hy r gen, methyl, flu0r0,or chloro and when Z phenhydramine hydrochloride; anesthetics such as is a single bond, R, can be either a or B oriented; benzocaine and lidocaine; antibacterials including io- 2 is hy g n, chloro, dine; iodochlorohydroxyquin, nitrofurazone, sulfanila- 3 is ketO mide and derivatives, and behzalkonium chloride; funa glcldes such as undecylentc acid vitamins such as Vitamin A derivatives; and other therapeutic agents including coal tar, balsam Peru, ammoniated mercury, anwherein R is hydrogen, hydroxy, chloro, or fluoro; thralin, chrysarobin, ichthammol, sulfur and the like. R is hydrogen, methyl, hydroxy, or a conventional The medicaments can be incorporated into this base hydrolyzable ester thereof;
7 R is hydrogen, hydroxy, a conventional hydrolyzable ester thereof, or when taken together with R,,',
wherein R is hydrogen or alkyl of up to eight carbons, and
R is hydrogen, or alkyl or an aryl group of up to eight carbons;
R is hydroxy, conventional hydrolyzable esters thereof, tetrahydropyranyloxy, tetrahydrofuranyloxy, 4-(lower)alkoxytetrahydropyran-4-yloxy, lower alkoxy, lower cycloalkoxy, lower cycloalkenyloxy, chloro, or fluoro;
R and R are hydrogen, methyl, phenyl, chlorophenyl, fluorophenyl, methylphenyl, or methoxyphenyl (the substituted phenyls preferably being substituted in the para position);
R and R each is hydrogen, chloro or fluoro;
Z, and Z each is a single bond, double bond, or
The terms (lower)alkyl and derivations thereof appearing in the above definitions and elsewhere in the instant specification denote alkyl groups having from one to six carbon atoms, inclusive, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, amyl, hexyl, and the like.
The term conventional hydrolyzable ester as used herein denotes those hydrolyzable ester groups conventional employed in the steriod art, preferably those derived from hydrocarbon carboxylic acids or phosphoric acids and their salts. The term hydrocarbon carboxylic acid" defines both substituted and unsubstituted hydrocarbon carboxylic acids. These acids can be completely saturated or possess varying degrees of unsaturation (including aromatic), can be of straight chain, branched chain, or cyclic structure, and preferably contain from one to 12 carbon atoms. In addition, they can be substituted by functional groups, for example, hydroxy, alkoxy containing up to six carbon atoms, acyloxy containing up to 12 carbon atoms, nitro, amino, halogeno, and the like, attached to the hydrocarbon backbone chain. Typical conventional hydrolyzable esters thus included within the scope of the term and the instant invention are acetate, propionate, butyrate, valerate, caproate, enanthate, caprylate, pelargonate, acrylate, undecenoate, phenoxyacetate, benzoate, phenylacetate, diphenylacetate, diethylacetate, trimethylacetate, t-butylacetate, trimethylhexanoate, methylneopentylacetate, cyclohexylacetate, cyclopentylpropionate, adamantoate, glycolate, methoxyacetate, hemisuccinate, hemiadipate, hemi-B,B-dimethylglutarate, acetoxyacetate, 2-chloro-4-nitrobenzoate, aminoacetate, diethylaminoacetate, piperidinoacetate, B-chloropropionate, trichloroacetate, B-chlorobutyrate, dihydrogen phosphate, dibenzyl phosphate, benzyl hydrogen phosphate, sodium benzyl phosphate, cyclohexylammonium benzyl phosphate, sodium phenyl phosphate, sodium ethyl phosphate, di-p-nitrobenzyl phosphate, sodium o-methoxyphenyl phosphate, cyclohexylammonium p-cyanobenzyl phosphate, sodium phenacyl phosphate, benzyl o-carbomethoxyphenyl phosphate, and the like.
By the term aryl are included aryl, aralkyl, and alkaryl groups, such as phenyl, p-chlorophenyl, pmethoxyphenyl, benzyl, phen'ethyl, tolyl, ethylphenyl, and the like. The wavy line I designates and includes both the alpha and beta configurations.
The above anti-inflammatory steroids have been previously disclosed in US. Pat. Nos. 3,365,446, 3,067,194, 3,364,203, 3,053,838 and 3,513,162, for example.
The above anti-inflammatory topical medicaments are thoroughly mixed with the base in therapeutically effective amounts. The particular concentration of the medicament in the base will vary depending upon the particular activity of the steroid used considered in conjunction with the condition and subject to be treated. In general, therapeutically effective amounts of these compounds can be as low as 0.00001 weight percent or lower, for example. For some uses, as high as 5 weight percent steroid or higher may be desired.
The medicament base of this invention has been found to be particularly suitable for use with topical corticoids, for example, 6a-fluoro-11 B-hydroxy- 16a,17a-isopropylidenedioxy-2lacetoxypregna-l ,4-diene-3 ,20-dione, fluocinolone acetonide (6a,9a-
difluoro-l 113,2 1 -dihydroxy-1 501,1 7a-isopropylidenedioxypregna-l ,4-diene-3,20-dione), fluocinolide 16aacetoxy-6a,9a-difluoro-l 1,8- hydroxy- 1 601,1 7a-isopropylidenedioxypregna-1 ,4- diene-3,20-dione), 901,1 1B-dichloro-6a-f1uoro-2lhydroxy-l601,17a'isopropylidenedioxypregna-l ,4-diene-3,20-dione, 911,1 1B-dichloro-6a,2ldifluoro- 1601,17a-isopropylidenedioxypregna-1,4-diene-3,20- dione and 901,1 18,21- trichloro-6a-fluoro-l 601,1 7a-isopropylidenedioxypregna-l ,4-diene-3,20-dione.
This invention is further illustrated by the following specific but non-limiting examples.
EXAMPLE 1 The following ingredients are mixed at 80C and cooled to room temperature with good agitation.
Concentration, Wt. Percent Ingredients Stearyl alcohol Sorbitan monostearate Polyoxyethylene sorbitan monostearate (Tween Propylene glycol Propylene carbonate Carboxy vinyl polymer (Carbopol) EXAMPLE 3 The following ingredients are mixed at 80C and cooled to room temperature with good agitation.
Ingredients Concentration, Wt. Percent Propylene carbonate 15.0 15.0 Dipropylene glycol 53.0 Propylene glycol 50.0 Stearyl alcohol 30.0 Cetyl alcohol 32.0 Carboxy vinyl polymer 1.0 (Carbopol) Sorbitan monostearate 1.0 3.0
EXAMPLE 4 Each of 0.25, 0.5 and 1.0 gm. quantities of the following anti-inflammatory steroids, when incorporated into 1,000 gm. the mixtures described in Example 1, are effective for topical treatment of inflammation:
901-1 1 3-dichloro-6a-fluoro-2 l -hydroxy-1 601,1 7a-isopropylidenedioxypregna-l ,4-diene-3,20-dione,
9a-fluoro-1 13,1 711,2 1 -trihydroxy- 1 63-methylpregna-1,4-diene-3,20-dione,
9a-fluoro- 1 13,21 -dihydroxy-l 63-methyl-1 7avaleroxypregna-l ,4-diene-3,20-dione,
l701,2l-dihydroxypregn-4-ene-3,1 1,20-trione,
l7a-hydroxy-2 l -acetoxypregn-4-ene-3,l 1,20-trione, 21-hydroxypregn-4-ene-3 ,20-dione, 21-acetoxypregn-4-ene-3,20-dione, 21-pivaloxypregn-4-3,20-dione,
9a-fluoro-l 13,17a,21-trihydroxy-l 6a-methylpregna-1,4-diene-3,20 -dione,
9a-fluoro-l 13,1701,21-trihydroxy-16a-methylpregna-l ,4-diene-3,20-dione-2 l-sodium phosphate,
6a,9a-difluoro-l l3,2l-dihydroxy-l6a,17a-isopropylidenedioxypregna- 1 ,4-diene-3,20-dione,
60:,9a-difluoro-1 l3-hydroxy-1 601,1 7a-isopropylidenedioxy-Z 1 -acetoxypregna-1 ,4-diene-3,20-dione,
60z-methyl-9a-fluoro-1 13,17a-dihydroxypregna-l,4- diene-3,20-dione,
6a-fluoro-1 13,1 701,2 1 -trihydroxypregna-1 ,4-diene- 3,20-dione, a-fluoro-l 13,21-dihydroxy-16a,l 7a-isopropylidenedioxypregn-4-ene-3,20-dione,
6a-fluoro-l l3,2l-dihydroxy-16a,17a-isopropylidenedioxypregna-l ,4-diene-3,20-dione,
1 13,170z-dihydroxy-21-acetoxypregn-4-ene-3,20- dione,
6a-methyl-1 13,1 711,2 l-trihydroxypregna-l ,4-diene- 3,20-dione, a-methyl-l 13,17a-dihydroxy-2l-acetoxypregna- 1 ,4-diene-3 ,20-dione,
6a-fluoro-l 13,17a,21-trihydroxy-16a-methylpregna-l,4-diene-3,20-dione,
6a-fluoro-l 13,170z-dihydroxy-l6a-methyl-21- acetoxypregna-l ,4-diene-3 ,20-dione,
6a-fluoro-l 13,17a-dihydroxy-l6a-methyl-2lvaleroxypregna- 1 ,4-diene-3 ,ZO-dione,
60z-fluoro-l l3-hydroxy-l6a,17a-isopropylidenedioxy-2 l -acetoxypregnal ,4-diene-3,20-dione,
113,17a,21-trihydroxypregna-l,4-diene-3,20-dione,
1 13,17a-dihydroxy-2l-acetoxypregna-l,4-diene- 3,20-dione,
l7a,2 1 -dihydroxypregna- 1 ,4-diene-3,l 1,20-trione,
l7a-hydroxy-2 l -acetoxypregna-l ,4-diene-3,l 1,20- trione,
9a-fluoro-1 13,16a,1704,2l-tetrahydroxypregna-l,4- diene-3,20-dione,
9a-fluoro-l 13,1601,17a-trihydroxy-2l-acetoxypregna-1,4-diene-3,20-dione,
9a-fluoro-1 13,2 1 -dihydroxy-1 601,1 7a-isopropylidenedioxypregna-l ,4-diene-3,20-dione,
6a-fluoro-9a,l l3-dichloro-1 602,1 7a-isopropylidenedioxy-2 1 -hydroxypregna-1 ,4-diene-3 ,20-dione,
6a,9a-difluoro-l 13,21-dihydroxy-16a-methyl-170zvaleroxypregna-l ,4-diene-3 ,20-dione,
6a,9a-difluoro-l 13,1701,2l-trihydroxy-l6a-methylpregna-l ,4-diene-3,20-dione,
6a,7a-difluoromethylene-l l3,17a,21-trihydroxypregn-4-ene-3,20-dione,
6a-fluoro-l 13,2 1 -dihydroxy- 1 a-methylpregna- 1 ,4- diene-3,20 dione,
6a,9a-difluoro-l l3-hydroxy-1 604,1 7a-isopropylidenedioxy-Z 1 -chloropregnal ,4-diene-3,20-dione,
901,1 13-dichloro-6a,2l-difluoro-16a,l7a-isopropylidenedioxypregna-l ,4-diene-3,20-dione', and
901,1 13,21-trichloro-6a-fluoro-16a,l 7a-isopropylidenedioxypregna-l ,4-diene-3 ,20-dione.
EXAMPLE 5 Repeating the procedure of Example 1 with a. from 5 to 40 percent of a fatty alcohol having from 16 to 24 carbons, e.g. cetyl alcohol, stearyl alcohol, behenyl alcohol, etc.;
b. from 1 to 40 percent of propylene carbonate;
c. from 25 to percent glycol cosolvent such as 1,2-
propanediol, 1,3-propanediol, polyethylene glycol (M.W. to 800), dipropylene glycol, etc., the weight ratio of the glycol solvent to propylene carbonate being at least 1:2;
d. a stabilizing quantity of a surfactant such as sorbitan monooleate; and
e. from 0 to 15 percent compatible plasticizer, e.g.,
carboxy vinyl polymer (Carbopol) yields an improved medicament base according to this invention.
EXAMPLE 6 Repeating the procedure of Example 4 with the ingredients of Example 5 yields improved compositions for topical treatment of inflammation according to this invention.
We claim:
1. A substantially anhydrous vehicle composition consisting essentially of a. from 5 to 40 weight percent of saturated fatty alcohol having from 16 to 24 carbons;
b. from 1 to 40 weight percent of propylene carbonate;
c. from 25 to 85 weight percent of glycol cosolvent,
weight ratio of the glycol solvent to propylene carbonate being at least 1:2;
d. a stabilizing amount of surfactant;
e. from to 15 weight percent of compatible plasticizer; and
f. from 0 to 3 weight percent water; said vehicle composition being particularly suitable for providing an occlusive film, for releasing topically active cortico-steroids which are soluble in propylene carbonate, and for distributing medication over the skin surface and maintaining it there until beneficial action occurs.
2. The composition of claim 1 comprising a. from to 30 weight percent of saturated fatty alcohol having from 16 to 24 carbons;
b. from 5 to 30 weight percent of propylene carbonate;
c. from 30 to weight percent of glycol cosolvent,
the weight ratio of glycol solvent to propylene carbonate being at least 1:1;
d. from 0.1 to 10 weight percent surfactant;
e. from O to 15 weight percent of compatible plasticizer, and
f. from O to 3 weight percent water.
3. The composition of claim 2 wherein the compatible plasticizer concentration is from 0.1 to 5 weight percent.
4. The composition of claim 1 wherein the weight ratio of the glycol cosolvent to propylene carbonate is at least 1:1.
5. The composition of claim 1 wherein the weight ratio of the glycol cosolvent to propylene carbonate is
Claims (5)
1. A SUBSTANTIALLY ANHYDROUS VEHICLE COMPOSITION CONSISTING ESSENTIALLY OF A. FROM 5 TO 40 WEIGHT PERCENT OF SATURATED FATTY ALOHOL HAVING FROM 16 TO 24 CARBONS; B. FROM 1 TO 40 WEIGHT PERCENT OF PROPYLENE CARBONATE; C. FROM 25 TO 85 WEIGHT PERCENT OF GLYCOL COSOLVENT, WEIGHT RATIO OF THE GLYCOL SOLVENT TO PROPYLENE CARBONATE BEING AT LEAST 1:2; D. A STABILIZING AMOUNT OF SURFACTANT, E. FROM 0 TO 15 WEIGNT PERCENT OF COMPATIBLE PLASTICIZER; AND F. FROM 0 TO 3 WEIGHT PERCENT WATER; SAID VEHICLE COMPOSITION BEING PARTICULARLY SUITABLE FOR PROVIDING AN OCCLUSIVE FILM, FOR RELEASING TOPICALLY ACTIVE CORTICO-STEROIDS WHICH ARE SOLUBLE IN PROPYLENE CARBONATE, AND FOR DISTRIBUTING, MEDICATION OVER THE SKIN SURFACE AND MAINTAINING IT THERE UNTIL BENEFICIAL ACTION OCCURS.
2. The composition of claim 1 comprising a. from 10 to 30 weight percent of saturated fatty alcohol having from 16 to 24 carbons; b. from 5 to 30 weight percent of propylene carbonate; c. from 30 to 80 weight percent of glycol cosolvent, the weight ratio of glycol solvent to propylene carbonate being at least 1:1; d. from 0.1 to 10 weight percent surfactant; e. from 0 to 15 weight percent of compatible plasticizer, and f. from 0 to 3 weight percent water.
3. The composition of claim 2 wherein the compatible plasticizer concentration is from 0.1 to 5 weight percent.
4. The composition of claim 1 wherein the weight ratio of the glycol cosolvent to propylene carbonate is at least 1:1.
5. The composition of claim 1 wherein the weight ratio of the glycol cosolvent to propylene carbonate is at least 3:1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201997A US3924004A (en) | 1971-11-24 | 1971-11-24 | Fatty alcohol-propylene carbonate-glycol solvent cream vehicle |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201997A US3924004A (en) | 1971-11-24 | 1971-11-24 | Fatty alcohol-propylene carbonate-glycol solvent cream vehicle |
Publications (1)
Publication Number | Publication Date |
---|---|
US3924004A true US3924004A (en) | 1975-12-02 |
Family
ID=22748155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US201997A Expired - Lifetime US3924004A (en) | 1971-11-24 | 1971-11-24 | Fatty alcohol-propylene carbonate-glycol solvent cream vehicle |
Country Status (1)
Country | Link |
---|---|
US (1) | US3924004A (en) |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4008321A (en) * | 1974-12-20 | 1977-02-15 | Toko Yakuhin Kogyo Kabushiki Kaisha | Composition for a topical preparation and a process for producing the same |
US4017615A (en) * | 1970-10-29 | 1977-04-12 | Syntex Corporation | Propylene carbonate ointment vehicle |
FR2382895A1 (en) * | 1977-03-07 | 1978-10-06 | Upjohn Co | PHARMACEUTICAL COMPOSITION BASED ON AN ANTI-INFLAMMATORY STEROID |
US4279901A (en) * | 1979-12-31 | 1981-07-21 | American Cyanamid Company | Topical ointment |
US4346086A (en) * | 1981-06-09 | 1982-08-24 | Beiersdorf Aktiengesellschaft | Corticosteroid-containing cream |
US4368188A (en) * | 1981-08-03 | 1983-01-11 | Eli Lilly And Company | Cosmetic toner formulation |
US4372944A (en) * | 1981-08-03 | 1983-02-08 | Eli Lilly And Company | Cosmetic cream formulation |
WO1984004681A1 (en) * | 1983-05-25 | 1984-12-06 | Alcon Lab Inc | Ophthalmic solution |
WO1984004680A1 (en) * | 1983-05-25 | 1984-12-06 | Alcon Lab Inc | Ophthalmic gel |
WO1985000106A1 (en) * | 1983-06-21 | 1985-01-17 | Stiefel Laboratories, Inc. | Improved compositions for the treatment of psoriasis |
US4496554A (en) * | 1979-01-17 | 1985-01-29 | E. R. Squibb & Sons, Inc. | Oleaginous emollient vehicle for steroid formulations |
US4501734A (en) * | 1981-03-06 | 1985-02-26 | Wakunaga Yakuhin Kabushiki Kaisha | Promotion of absorption of drugs administered through the alimentary system |
US4626539A (en) * | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
EP0215622A2 (en) | 1985-09-09 | 1987-03-25 | Syntex (U.S.A.) Inc. | Naphthalene anti-psoriatic agents and process for making them |
US4738851A (en) * | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
US4954346A (en) * | 1988-06-08 | 1990-09-04 | Ciba-Geigy Corporation | Orally administrable nifedipine solution in a solid light resistant dosage form |
US4954487A (en) * | 1979-01-08 | 1990-09-04 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
US4963555A (en) * | 1980-07-18 | 1990-10-16 | Burroughs Wellcome Co. | Formulations of heterocyclic compounds |
US5034420A (en) * | 1983-06-09 | 1991-07-23 | Bristol-Myers Squibb Co. | Compositions and method for stabilization of anthralin comprising the addition of an oil soluble antioxidant and an anionic surfactant |
US5102656A (en) * | 1983-07-29 | 1992-04-07 | The Mennen Company | Antiperspirant creams |
US5635497A (en) * | 1982-06-23 | 1997-06-03 | Yamanouchi Europe B.V. | Topical application compositions |
US6140285A (en) * | 1998-07-30 | 2000-10-31 | Charlotte-Mecklenburg Hospital Authority | Use of dioctyl sulfosuccinate salts for cleaning petroleum contaminated surfaces |
US20040106523A1 (en) * | 2001-03-28 | 2004-06-03 | Stridde Howard M. | Alkylene carbonate adjuvants |
EP1875905A2 (en) | 2003-04-28 | 2008-01-09 | Bayer Schering Pharma Aktiengesellschaft | Pharmaceutical compound in the form of a hydrogel for transdermal application of active substances |
US20100160454A1 (en) * | 2008-12-22 | 2010-06-24 | Eastman Chemical Company | Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products |
US20110028566A1 (en) * | 2009-05-15 | 2011-02-03 | Eastman Chemical Company | Compositions and products containing cycloaliphatic diol antimicrobial agents and methods of using the compositions and products |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3136696A (en) * | 1961-02-17 | 1964-06-09 | Corby Entpr Inc | Shaving assisting composition |
US3178352A (en) * | 1959-02-27 | 1965-04-13 | Erickson Roy | Shaving method and composition therefor |
US3185627A (en) * | 1954-09-03 | 1965-05-25 | Hazel Bishop Inc | Silicone composition |
US3298919A (en) * | 1962-12-26 | 1967-01-17 | Dow Corning | Shaving cream containing polysiloxanes |
US3352753A (en) * | 1965-03-19 | 1967-11-14 | Squibb & Sons Inc | Pharmaceutical compositions of corticosteroids in gelled alcohol |
US3472931A (en) * | 1969-01-17 | 1969-10-14 | Foster Milburn Co | Percutaneous absorption with lower alkyl amides |
US3574118A (en) * | 1967-07-03 | 1971-04-06 | Colgate Palmolive Co | Aerosol foam composition suitable for dispensing when warm |
US3592930A (en) * | 1968-07-19 | 1971-07-13 | Syntex Corp | Moisture-deterioratable topical medicaments,particularly anti-inflammatory steroids,in a substantially non-aqueous fatty alcohol-propylene glycol vehicle |
-
1971
- 1971-11-24 US US201997A patent/US3924004A/en not_active Expired - Lifetime
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3185627A (en) * | 1954-09-03 | 1965-05-25 | Hazel Bishop Inc | Silicone composition |
US3178352A (en) * | 1959-02-27 | 1965-04-13 | Erickson Roy | Shaving method and composition therefor |
US3136696A (en) * | 1961-02-17 | 1964-06-09 | Corby Entpr Inc | Shaving assisting composition |
US3298919A (en) * | 1962-12-26 | 1967-01-17 | Dow Corning | Shaving cream containing polysiloxanes |
US3352753A (en) * | 1965-03-19 | 1967-11-14 | Squibb & Sons Inc | Pharmaceutical compositions of corticosteroids in gelled alcohol |
US3574118A (en) * | 1967-07-03 | 1971-04-06 | Colgate Palmolive Co | Aerosol foam composition suitable for dispensing when warm |
US3592930A (en) * | 1968-07-19 | 1971-07-13 | Syntex Corp | Moisture-deterioratable topical medicaments,particularly anti-inflammatory steroids,in a substantially non-aqueous fatty alcohol-propylene glycol vehicle |
US3472931A (en) * | 1969-01-17 | 1969-10-14 | Foster Milburn Co | Percutaneous absorption with lower alkyl amides |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4017615A (en) * | 1970-10-29 | 1977-04-12 | Syntex Corporation | Propylene carbonate ointment vehicle |
US4008321A (en) * | 1974-12-20 | 1977-02-15 | Toko Yakuhin Kogyo Kabushiki Kaisha | Composition for a topical preparation and a process for producing the same |
FR2382895A1 (en) * | 1977-03-07 | 1978-10-06 | Upjohn Co | PHARMACEUTICAL COMPOSITION BASED ON AN ANTI-INFLAMMATORY STEROID |
US4954487A (en) * | 1979-01-08 | 1990-09-04 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
US4496554A (en) * | 1979-01-17 | 1985-01-29 | E. R. Squibb & Sons, Inc. | Oleaginous emollient vehicle for steroid formulations |
US4279901A (en) * | 1979-12-31 | 1981-07-21 | American Cyanamid Company | Topical ointment |
US4963555A (en) * | 1980-07-18 | 1990-10-16 | Burroughs Wellcome Co. | Formulations of heterocyclic compounds |
US4501734A (en) * | 1981-03-06 | 1985-02-26 | Wakunaga Yakuhin Kabushiki Kaisha | Promotion of absorption of drugs administered through the alimentary system |
US4346086A (en) * | 1981-06-09 | 1982-08-24 | Beiersdorf Aktiengesellschaft | Corticosteroid-containing cream |
US4368188A (en) * | 1981-08-03 | 1983-01-11 | Eli Lilly And Company | Cosmetic toner formulation |
US4372944A (en) * | 1981-08-03 | 1983-02-08 | Eli Lilly And Company | Cosmetic cream formulation |
US5635497A (en) * | 1982-06-23 | 1997-06-03 | Yamanouchi Europe B.V. | Topical application compositions |
WO1984004681A1 (en) * | 1983-05-25 | 1984-12-06 | Alcon Lab Inc | Ophthalmic solution |
WO1984004680A1 (en) * | 1983-05-25 | 1984-12-06 | Alcon Lab Inc | Ophthalmic gel |
US5034420A (en) * | 1983-06-09 | 1991-07-23 | Bristol-Myers Squibb Co. | Compositions and method for stabilization of anthralin comprising the addition of an oil soluble antioxidant and an anionic surfactant |
US4551480A (en) * | 1983-06-21 | 1985-11-05 | Stiefel Laboratories, Inc. | Compositions for the treatment of psoriasis |
WO1985000106A1 (en) * | 1983-06-21 | 1985-01-17 | Stiefel Laboratories, Inc. | Improved compositions for the treatment of psoriasis |
US5102656A (en) * | 1983-07-29 | 1992-04-07 | The Mennen Company | Antiperspirant creams |
US4626539A (en) * | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
EP0215622A2 (en) | 1985-09-09 | 1987-03-25 | Syntex (U.S.A.) Inc. | Naphthalene anti-psoriatic agents and process for making them |
US4738851A (en) * | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
US4954346A (en) * | 1988-06-08 | 1990-09-04 | Ciba-Geigy Corporation | Orally administrable nifedipine solution in a solid light resistant dosage form |
US6140285A (en) * | 1998-07-30 | 2000-10-31 | Charlotte-Mecklenburg Hospital Authority | Use of dioctyl sulfosuccinate salts for cleaning petroleum contaminated surfaces |
US20040106523A1 (en) * | 2001-03-28 | 2004-06-03 | Stridde Howard M. | Alkylene carbonate adjuvants |
US7297660B2 (en) | 2001-03-28 | 2007-11-20 | Huntsman Petrochemical Corporation | Alkylene carbonate adjuvants |
EP1875905A2 (en) | 2003-04-28 | 2008-01-09 | Bayer Schering Pharma Aktiengesellschaft | Pharmaceutical compound in the form of a hydrogel for transdermal application of active substances |
US20100160454A1 (en) * | 2008-12-22 | 2010-06-24 | Eastman Chemical Company | Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products |
US20110028566A1 (en) * | 2009-05-15 | 2011-02-03 | Eastman Chemical Company | Compositions and products containing cycloaliphatic diol antimicrobial agents and methods of using the compositions and products |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3924004A (en) | Fatty alcohol-propylene carbonate-glycol solvent cream vehicle | |
US3592930A (en) | Moisture-deterioratable topical medicaments,particularly anti-inflammatory steroids,in a substantially non-aqueous fatty alcohol-propylene glycol vehicle | |
US4305936A (en) | Topical corticosteroid formulations | |
CA1067409A (en) | Anti-inflammatory composition containing corticosteroids | |
US4185100A (en) | Topical anti-inflammatory drug therapy | |
US4017615A (en) | Propylene carbonate ointment vehicle | |
US3749773A (en) | Gelled steroid ointment | |
US5061700A (en) | Glyceryl acetate ointment vehicles | |
US3892857A (en) | Steroid formulation | |
US4579844A (en) | Topical anti-inflammatory drug therapy | |
US3888995A (en) | Fatty alcohol-propylene glycol vehicle | |
JPS6281318A (en) | Cream containing hydrocortisone diester | |
EP0216303B1 (en) | External medication | |
US4360518A (en) | Topical anti-inflammatory drug therapy | |
GB1317184A (en) | Steroid-containing pharmaceutical preparations | |
US4473565A (en) | Topical anti-inflammatory drug therapy | |
EP1194109B1 (en) | Topical formulations comprising skin penetration agents and the use thereof | |
JPH0676327B2 (en) | Steroid ointment formulation | |
US5036050A (en) | Compositions containing thymopentin for topical treatment of skin disorders | |
CA1146863A (en) | Topical ointment | |
US6979454B1 (en) | Biologically active composition | |
US3284303A (en) | Orally active progesterone compositions | |
JPS589081B2 (en) | Vehicle composition | |
JPH05331066A (en) | Composition for treatment of acne vulgaris | |
DE2309448A1 (en) | PREPARATORY OR CARRIER |